Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma

Independent Research and Laboratory Solutions (ILS), 240 Klisthenous Str., 153 44, Gerakas, Athens, Greece.
Biomedical Chromatography (Impact Factor: 1.66). 06/2005; 19(5):394-401. DOI: 10.1002/bmc.465
Source: PubMed

ABSTRACT An improved liquid chromatographic tandem mass spectrometric method for the determination of glimepiride in human plasma has been developed and fully validated. The article describes in detail the bioanalytical procedure and summarizes the validation results obtained. The samples were extracted using liquid--liquid extraction with a mixture of 1-chlorobutane-isopropanol-ethyl acetate (88:2:10, v/v/v). The chromatographic separation was performed on a reversed-phase Hypersil ODScolumn (250 x 4.6 mm i.d.; 5 microm particle size) using a mobile phase consisting of formic acid 0.05 M-acetonitrile (28:72, v/v), pumped at a flow rate of 0.3 ml min(-1) heated to 25 degrees C. The analytes were detected using an API 3000 triple quadrupole mass spectrometer with positive electrospray ionization in multiple reaction monitoring mode. Tandem mass spectrometric detection enabled the quantitation of glimepiride down to 0.50 ng mL(-1). Calibration graphs were linear (r better than 0.998, n=1), in concentration range 0.50--1000 ng mL(-1), and the intra- and inter- day RSD values were less than 10.37 and 11.55% for glimepiride. The method was successfully applied to a kinetic study in order to assess the main pharmacokinetic parameters of glimepiride.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: A simple, precise, and accurate high-performance thin-layer chromatography (HPTLC) method for the simultaneous determination of pioglitazone, metformin, and glimepiride in multicomponent pharmaceutical preparations has been developed and validated. Pioglitazone, metformin, and glimepiride from the formulations were separated on silica gel 60 F(254) HPTLC plates with acetonitrile, methanol, propyl alcohol, and ammonium acetate solutions in the proportion of 7:2:1:1 (v/v) as mobile phase. Densitometric quantification was performed at 240 nm. Well-resolved bands were obtained with R(F). values 0.83, 0.21, and 0.89 for pioglitazone, metformin, and glimepiride, respectively. The method was validated for precision, accuracy, specificity, and robustness. The calibration curve was found to be linear in the concentration range of 0.3-1.2, 10-40, and 0.04-0.16 mu g per band by area with correlation coefficients of 0.995, 0.996, and 0.998 for pioglitazone, metformin, and glimepiride, respectively. The method is selective and specific, with potential application in pharmaceutical analysis of these drugs in bulk and formulations.
    JPC - Journal of Planar Chromatography - Modern TLC 08/2011; 24(4):331-336. DOI:10.1556/JPC.24.2011.4.11 · 0.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A sensitive and rapid ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method was developed to determine glimepiride (GPD) and fluoxetine (FLU) in human plasma using diazepam as the internal standard (IS) simultaneously. The presented method used an Acquity UPLC BEH C18 column for chromatographic separation with tandem mass spectrometric detection on a QTrap5500 mass spectrometer operated in positive ESI mode. The mobile phase is a mixture of acetonitrile and 1% formic acid in water with gradient elution at a flow rate of 0.40mL/min. The GPD, FLU and IS were eluted at 1.46, 1.27 and 1.39min, respectively. The MRM transitions of m/z 491.3→126.3 and m/z 310.5→148.1 were used to quantify for GPD and FLU, respectively. The linearity of this method was found to be within the concentration range of 2.5-300ng/mL and 0.1-20ng/mL for GPD and FLU in human plasma, respectively. The intra- and inter-day precision (RSD%) were less than 10.3% and accuracy (RE%) was within ±7.3%. The matrix effect were 95.3-100.7% for GPD and FLU. GPD and FLU were sufficiently stable under all relevant analytical conditions. The method was also successfully applied to the clinical samples after a single oral dose of 2mg GLP and 40mg FLU in patients. Copyright © 2014 Elsevier B.V. All rights reserved.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 12/2014; 980C:16-19. DOI:10.1016/j.jchromb.2014.12.023 · 2.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study, a simple method using microextraction by packed sorbent and high-performance liquid chromatography with ultraviolet detection for simultaneous determination of chlorpropamide, gliclazide and glimepiride in human plasma was developed and validated. A fractional factorial design and a complete factorial design were applied to evaluate the parameters which could affect the extraction and desorption steps, respectively. All parameters in the extraction step (pH, sample volume, sample dilution and number of aspiration/ejection cycles) and in the desorption step (percentage of acetonitrile in the elution solvent and number of aspirations of elution solvent through the device) were statistically significant (p>0.05) when recovery was used as response. The developed method allowed the use of small volumes of sample and solvents and rapid separation by using a fused core column (only 2.2min were needed). This method was fully validated showing selectivity, precision, accuracy and linearity over the range 1.0-50.0μgmL(-1) for chlorpropamide, 1.0-10.0μgmL(-1) for gliclazide and 0.1-1.0μgmL(-1) for glimepiride. Finally, the validated method was applied in the analysis of samples from volunteers containing the three tested analytes.
    Journal of pharmaceutical and biomedical analysis 04/2014; 96C:241-248. DOI:10.1016/j.jpba.2014.03.042 · 2.83 Impact Factor